UPDATE: Deutsche Bank Downgraded ResMed on Disappointing Sales Forecast
October 25, 2013 at 12:14 PM EDT
In a report published Friday, Deutsche Bank Markets Research analyst David Low downgraded ResMed Inc. (NYSE: RMD ) from Buy to Hold and maintained their $54 PT based on a disappointing sales forecast. Although the medium term outlook remains positive, ResMed suffered market share pressure from Competitive Bidding Round 2
